GSK Receives FDA Fast Track Designation for Bepirovirsen in Chronic Hepatitis B GSK plc has revealed that the US Food and Drug Administration (FDA) has awarded Fast Track status to bepirovirsen, an experimental antisense oligonucleotide (ASO) designed to treat chronic hepatitis B (CHB). Fast Track designation ai...
Find MoreEisai Submits Marketing Authorization Application In Japan for Anticancer Agent Tasurgratinib For Biliary Tract Cancer With FGFR2 Gene Fusion Eisai Co., Ltd. has officially submitted a request for marketing authorization in Japan for tasurgratinib succinate, its internally developed tyrosine kinase inhibitor tar...
Find MoreIncyte Halts Phase III Clinical Trial for Myelofibrosis Incyte announced the termination of Phase III LIMBER-304 trial after the results of a pre-planned interim analysis conducted by an independent data monitoring committee (IDMC) revealed that the study is unlikely to meet the primary endpoint in the int...
Find MoreGene Therapy: The “Hunt” for CNS disorders! Many companies have tried over the years to find a way to reverse the course of crippling central nervous system disorders like amyotrophic lateral sclerosis (a.k.a. Lou Gehrig’s disease) but have failed. Fortunately, Gene therapy has proven to be an answer to a wide ran...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!